Remove Leads Remove Prospecting Remove Safety
article thumbnail

Safety Risk Sinks Cargo Therapeutics’ Cancer Cell Therapy Prospect, Leading to 50% Staff Cut

MedCity News

The post Safety Risk Sinks Cargo Therapeutics Cancer Cell Therapy Prospect, Leading to 50% Staff Cut appeared first on MedCity News. Phase 2 data for Cargo Therapeutics CD22-targeting cell therapy show low durability and cases of a severe immune response, some that were classified as grade 4 or 5 serious adverse events.

article thumbnail

VR Training For Medical Device Maintenance Personnel

Infuse Medical

Brief Overview of the Importance of Medical Device Maintenance Medical device maintenance ensures patient safety, operational efficiency, and regulatory compliance in healthcare settings. Regular maintenance helps prevent device malfunctions that could lead to incorrect diagnoses, treatment delays, or patient harm.

Training 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AR Applications For Healthcare Professionals

Infuse Medical

This improves doctor-patient communication and leads to more accurate diagnosis and treatment planning. Future Prospects and Challenges 1. Future Prospects of AR in the Hospital Sector AR technology is doing great in the hospital industry. Here are the future prospects of AR in the hospital sector.

article thumbnail

Ipsen’s rare disease drug palovarotene knocked back in EU

pharmaphorum

It refiled in the US, but got a complete response from the FDA in December with a request for more clinical information that has delayed the programme even further, and the CHMP’s decision will further undermine confidence in the drug’s prospects.

FDA 98
article thumbnail

Developing the EU’s first intestinal microbiota-based biologic

European Pharmaceutical Review

The main objective was to evaluate the efficacy and safety of MBK-01 compared to fidaxomicin, providing significant insights into the potential of MBK-01 as a treatment for primary or recurrent CDI and contributing to the advancement of microbiome-based therapies. The study included 92 adult patients with confirmed CDI.

Safety 111
article thumbnail

Can the FDA keep the momentum going for rare disease drug approvals?

Pharmaceutical Technology

The mutation leads to disordered thyroid hormone transport, which causes patients to experience intellectual and motor disabilities. DMD pathology is caused by a lack of dystrophin protein, leading to the weakening and damage of muscle cells progressively over time. In clinical trials, the drug showed a 3.8-point compared to 38.5%

FDA 126
article thumbnail

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results for GA

pharmaphorum

Wykoff about the results from Apellis Pharmaceuticals’ OAKS study on intravitreal pegcetacoplan for geographic atrophy (GA), otherwise known as atrophic or dry age-related macular degeneration (AMD), a leading cause of blindness worldwide. Bleak prospects, indeed. The specifics of an exciting prospect.

Safety 105